By this point, deep in the second decade of the twenty-first century, the computer and the Internet have permeated virtually every aspect of mental health treatment and research, from the patient encounter documented in the electronic health record to the enormous databases of insurance claims and prescription records stored in servers around the globe.
Ironically, psychiatry was relatively late to the party. For much of its existence, the field was adamantly analogue, placing more emphasis on the individual patient's symptoms, functioning, relationships, and psychodynamics, than any aggregation of data. Indeed, many clinicians in practice today can still identify Freud's most famous patients by name. Treasure troves of old records, such as those found in the Phipps Psychiatric Clinic of Johns Hopkins Hospital [1] and the Iowa State Psychopathic Hospital [2] in the prepsychopharmacology era, provided fascinating case studies, which were eventually combined to better understand the natural trajectory of serious, unmedicated mental illness. But it may well have been the mid-twentieth century development of drugs to treat mental disorders that introduced the field to the need for, and benefit of, systematic data collection in the course of psychiatric evaluation and therapy, and of categorizing patients by reasonably valid and reliable diagnoses. Once available, the computer and the ''cloud'' became important tools in the collation, storage, and analysis of such data.
Fast forward to today, and nearly every aspect of each patient-clinician encounter is preserved for clinical, accounting, and/or research purposes. The electronic medical record, while perhaps the most thorough account of the evaluation and treatment course of any given patient, is usually least accessible for research, as its plethora of identifying information and narrative form present both privacy and practical impediments. More inviting is the growing array of large centralized databases collected and stored away from and independent of sites of actual clinical practice, affording the opportunity for rapid review and analysis of a wealth of de-identified information on hundreds or thousands of patients. Key examples of such data repositories are those derived from insurance claims and, the subject of a major report in the current issue of CNS Drugs [3] , those containing longitudinal pharmacy records of prescribed medications.
The wealth of information available to investigators in insurance and pharmacy records ranges from diagnoses to treatment plans, from clinical state to adverse effects. An entire field of ''pharmacoepidemiology'' has been built upon the new opportunity to assess the use of medications on a grand, even national or international, scale. As the new report on antidepressant adherence in the present issue illustrates [3] , researchers and practitioners alike must be wary of the limitations, as well as the value, of currently available ''big data.'' On the positive side, the opportunities for creative and clinically and policy practice, such as the growing rate of prescriptions of atypical antipsychotics in young people [4] and of stimulants in adults [5] , and in identifying potentially inappropriate prescribing to vulnerable populations, such as the elderly [6] . However, the interpretation of such prescription data can be challenging. In large part, this is due to the growing fragmentation and segregation of available information about patients and their treatments, particularly the disconnect between clinical and pharmaceutical data. The detailed prescription information available for study often is associated with patients who are so ''de-identified'' that little corresponding clinical information is available to help make sense of the pharmacy data. Continuous prescribing and refills over a period of time suggest but cannot prove good adherence, whereas interruptions in prescribing often equate with poor compliance-but could be due to serious adverse effects, pregnancy, the onset of rapid cycling, or a host of other clinical developments not typically documented in pharmacy records. Even continuous filling of prescriptions says nothing about the extent to which the medication is actually helping. Patients may be adherent to an ineffective drug for many weeks, with or without the doctor's encouragement.
These many possible confounding variables mandate a note of caution in comparing patients' experiences based on pharmaceutical databases. As thoughtfully reviewed in the study by Keyloun et al. [3] in the current issue, large prescription databases can be used to demonstrate differences in apparent adherence across classes of antidepressant medications. However, the lack of relevant information on possible differential prescribing patterns between generalists and specialists, and differences in indications beyond depression, prevent definitive conclusions from a retrospective look at naturalistic pharmacy data without additional information about the patients and the prescribers.
Beyond basic demographic information, the inclusion of diagnosis in large healthcare-related databases, such as those with pharmacy or genetic profiles, can be especially relevant in research with drugs such as antidepressants, which are often prescribed for conditions other than unipolar major depression. In the context of bipolar disorder, for example, should an antidepressant be felt to contribute to a mood switch or rapid cycling, its seemingly early discontinuation could represent a reasonable intervention by the clinician, not a failure of adherence on the part of the patient. The now-common off-label use of lowdose trazodone as a hypnotic in patients with depression [7] can present a misleading picture of apparent poor antidepressant adherence in pharmacy records because of seemingly inadequate dose and duration criteria.
At the same time, it must be recognized that the ''chart diagnosis'' entered into pharmacy databases cannot always be taken at face value. In contrast to research diagnoses established through the use of structured interviews and all available records and informants, clinical diagnoses are often more impressionistic and less anchored to established diagnostic criteria. Moreover, sometimes the diagnosis of record may be softened or sanitized in the interest of protecting the patient from censure or disparagement; in some settings, ''bipolar disorder'' is considered more socially acceptable than ''borderline personality disorder,'' for example, and concomitant alcohol or substance abuse or dependence may be omitted from the diagnostic listing. While this is problematic enough in the clinical care of the patient, it can seriously undermine the productive analysis of relevant pharmacy or genetic data.
The continuing development of the US National Institute of Mental Health (NIMH) Research Domain Criteria (RDoC) project [8] is encouraging efforts at studying specific symptoms, or constructs, such as cognition or anhedonia as targets of antidepressant or antipsychotic pharmacotherapy. As that work proceeds, pharmacy ''big data,'' augmented by correlated clinical documentation, may help match patients with optimal treatments across traditional diagnostic boundaries.
Increasingly, the field is finding that more comprehensive, rather than segmented databases-even within the individual patient's electronic health record [9] -can create better platforms for clinical and epidemiological research. Advances in ''cloud''-based technologies now make possible the relatively seamless integration of data from across healthcare systems, as evidenced, for example, in the NIMH-supported Mental Health Research Network, the pan-Canadian Primary Care Sentinel Surveillance Network, and the nonprofit patient-centered PCORnet clinical research network [10] . These networks can both provide large amounts of ''real world'' clinical and corresponding pharmacy data and serve as a platform for prospective effectiveness research [11] .
The promise and current limitations of big data to address clinical issues, and the value of incorporating clinical information into prescription databases, are illustrated by recent efforts at using the near-universal health records in two Scandinavian countries to address a timely and vexing question: Can the use of hormonal birth control products cause depression? First, the Swedish Prescribed Drug Register, which covers the entire national population and impressively collects data ''directly from the cashier's computer to the register,'' was searched for concomitant use of oral and parenteral hormonal contraceptives and antidepressants [12] . Compared with non-hormonal contraceptive users, women prescribed several classes of birth control, most notably users of injected and other non-oral progestin-only products, had an odds ratio for antidepressant prescriptions significantly [1 in all age groups [12] . However, in the absence of clinical records, the inability of the prescription database to identify the sequence of contraceptive and antidepressant use forced the investigators to conclude that they could detect only ''usage patterns'' of the two drugs and not causality [12] .
One solution to this quandary was presented by the even more comprehensive health records accessible to investigators in Denmark, where the unique personal identification number issued to all citizens permits ''reliable linkage'' among all public registries [12] . In this case, the National Prescription Register, capturing ''98.7% of all antidepressants used in Denmark'' was combined with the Psychiatric Central Research Register, which recorded first inpatient and outpatient discharge diagnoses of depression. Using de-identified but related data from both prescription and clinical databases, the Danish investigators were able to present a more definitive conclusion that all types of hormonal contraception, especially those predominantly progesterone-based, were associated with a subsequent diagnosis of depression and prescription of antidepressant medication [13] .
Taking this confluence of registries still further, Danish investigators recently addressed another timely clinical issue in the treatment of depression: reconciling the presumably therapeutic anti-inflammatory properties of lipidlowering statin drugs with evidence for increased suicidality associated with low cholesterol levels. With the prescription and psychiatric registries noted above, they were able to access information on virtually everyone who had received a selective serotonin reuptake inhibitor (SSRI) in Denmark over a 15-year period (almost 900,000 individuals), more than 100,000 of whom were concomitantly treated with a statin drug [14] . With additional information from the Danish National Patient Register, the Danish Civil Registration System, and the Cause of Death Register-all linked through individuals' unique personal registration numbers-a positive effect of combined treatment (reduced psychiatric hospital contacts) was documented, along with no increased risk of suicidality in individuals who received both an SSRI and a statin [14] .
With appropriate attention to the limitations noted, large pharmacy and similar databases, especially when analyzed in conjunction with corresponding clinical and demographic information, are important tools in achieving one of the field's main, and still elusive goals-the personalization of treatment.
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